Real-world experiences in migraine therapy with rizatriptan

Dara Jamieson, F. Michael Cutrer, Jerome Goldstein, Jeffrey Dayno, X. Henry Hu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective. - To evaluate the effectiveness of rizatriptan for acute migraine treatment and patient satisfaction with the drug in usual clinical practice settings. Background. - Although rizatriptan has been shown to effectively relieve migraine symptoms in clinical trials, we wished to assess its utility in typical patient care settings. Design. - Multicenter, open-label design involving the patients of practicing clinicians. Methods. - Adult migraineurs treated two migraine attacks with either rizatriptan 10-mg standard tablets or rizatriptan 10-mg orally disintegrating tablets in a crossover manner. Participants had not taken rizatriptan previously and chose which formulation to take first. Patients reported their treatment experiences via an interactive voice response system approximately 24 hours after treatment. Prior migraine treatment experiences were reported by patients on a baseline questionnaire completed at participating clinics. We used conditional logistic regression analysis adjusted for treatment sequences to test the statistical significance of comparisons with results recorded on the baseline questionnaire. Results. - Of the 5388 patients enrolled, 3953 (73%) completed at least one follow-up and 3183 (59%) completed two follow-up reports. Patients reported the following outcomes for attacks treated with the rizatriptan tablet and orally disintegrating tablet formulations, respectively, compared with their prior responses to oral usual care medications (P<.05 in all comparisons with baseline data): onset of pain relief within 30 minutes postdose: 18% and 23% versus 16%; no or mild headache 2 hours postdose: 66% and 67% versus 37%; largely symptom-free within 2 hours postdose: 52% and 54% versus 35%; return to usual activities within 2 hours postdose: 50% and 51% versus 31%; and very or somewhat satisfied with treatment: 72% and 74% versus 53%. Conclusions. - In this "real-world" setting involving a patient population selected by clinicians, rizatriptan appeared to offer better treatment outcomes than those from prior treatments with other oral migraine medications.

Original languageEnglish (US)
Pages (from-to)223-230
Number of pages8
JournalHeadache
Volume43
Issue number3
DOIs
StatePublished - Mar 2003

Fingerprint

Migraine Disorders
Tablets
Therapeutics
rizatriptan
Patient Satisfaction
Headache
Patient Care
Logistic Models
Regression Analysis
Clinical Trials
Pain
Pharmaceutical Preparations
Population

Keywords

  • Migraine
  • Rizatriptan
  • Treatment
  • Usual clinic practice

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Jamieson, D., Cutrer, F. M., Goldstein, J., Dayno, J., & Hu, X. H. (2003). Real-world experiences in migraine therapy with rizatriptan. Headache, 43(3), 223-230. https://doi.org/10.1046/j.1526-4610.2003.03045.x

Real-world experiences in migraine therapy with rizatriptan. / Jamieson, Dara; Cutrer, F. Michael; Goldstein, Jerome; Dayno, Jeffrey; Hu, X. Henry.

In: Headache, Vol. 43, No. 3, 03.2003, p. 223-230.

Research output: Contribution to journalArticle

Jamieson, D, Cutrer, FM, Goldstein, J, Dayno, J & Hu, XH 2003, 'Real-world experiences in migraine therapy with rizatriptan', Headache, vol. 43, no. 3, pp. 223-230. https://doi.org/10.1046/j.1526-4610.2003.03045.x
Jamieson D, Cutrer FM, Goldstein J, Dayno J, Hu XH. Real-world experiences in migraine therapy with rizatriptan. Headache. 2003 Mar;43(3):223-230. https://doi.org/10.1046/j.1526-4610.2003.03045.x
Jamieson, Dara ; Cutrer, F. Michael ; Goldstein, Jerome ; Dayno, Jeffrey ; Hu, X. Henry. / Real-world experiences in migraine therapy with rizatriptan. In: Headache. 2003 ; Vol. 43, No. 3. pp. 223-230.
@article{5a08c83ad04444f1b28541c2f1b80a90,
title = "Real-world experiences in migraine therapy with rizatriptan",
abstract = "Objective. - To evaluate the effectiveness of rizatriptan for acute migraine treatment and patient satisfaction with the drug in usual clinical practice settings. Background. - Although rizatriptan has been shown to effectively relieve migraine symptoms in clinical trials, we wished to assess its utility in typical patient care settings. Design. - Multicenter, open-label design involving the patients of practicing clinicians. Methods. - Adult migraineurs treated two migraine attacks with either rizatriptan 10-mg standard tablets or rizatriptan 10-mg orally disintegrating tablets in a crossover manner. Participants had not taken rizatriptan previously and chose which formulation to take first. Patients reported their treatment experiences via an interactive voice response system approximately 24 hours after treatment. Prior migraine treatment experiences were reported by patients on a baseline questionnaire completed at participating clinics. We used conditional logistic regression analysis adjusted for treatment sequences to test the statistical significance of comparisons with results recorded on the baseline questionnaire. Results. - Of the 5388 patients enrolled, 3953 (73{\%}) completed at least one follow-up and 3183 (59{\%}) completed two follow-up reports. Patients reported the following outcomes for attacks treated with the rizatriptan tablet and orally disintegrating tablet formulations, respectively, compared with their prior responses to oral usual care medications (P<.05 in all comparisons with baseline data): onset of pain relief within 30 minutes postdose: 18{\%} and 23{\%} versus 16{\%}; no or mild headache 2 hours postdose: 66{\%} and 67{\%} versus 37{\%}; largely symptom-free within 2 hours postdose: 52{\%} and 54{\%} versus 35{\%}; return to usual activities within 2 hours postdose: 50{\%} and 51{\%} versus 31{\%}; and very or somewhat satisfied with treatment: 72{\%} and 74{\%} versus 53{\%}. Conclusions. - In this {"}real-world{"} setting involving a patient population selected by clinicians, rizatriptan appeared to offer better treatment outcomes than those from prior treatments with other oral migraine medications.",
keywords = "Migraine, Rizatriptan, Treatment, Usual clinic practice",
author = "Dara Jamieson and Cutrer, {F. Michael} and Jerome Goldstein and Jeffrey Dayno and Hu, {X. Henry}",
year = "2003",
month = "3",
doi = "10.1046/j.1526-4610.2003.03045.x",
language = "English (US)",
volume = "43",
pages = "223--230",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Real-world experiences in migraine therapy with rizatriptan

AU - Jamieson, Dara

AU - Cutrer, F. Michael

AU - Goldstein, Jerome

AU - Dayno, Jeffrey

AU - Hu, X. Henry

PY - 2003/3

Y1 - 2003/3

N2 - Objective. - To evaluate the effectiveness of rizatriptan for acute migraine treatment and patient satisfaction with the drug in usual clinical practice settings. Background. - Although rizatriptan has been shown to effectively relieve migraine symptoms in clinical trials, we wished to assess its utility in typical patient care settings. Design. - Multicenter, open-label design involving the patients of practicing clinicians. Methods. - Adult migraineurs treated two migraine attacks with either rizatriptan 10-mg standard tablets or rizatriptan 10-mg orally disintegrating tablets in a crossover manner. Participants had not taken rizatriptan previously and chose which formulation to take first. Patients reported their treatment experiences via an interactive voice response system approximately 24 hours after treatment. Prior migraine treatment experiences were reported by patients on a baseline questionnaire completed at participating clinics. We used conditional logistic regression analysis adjusted for treatment sequences to test the statistical significance of comparisons with results recorded on the baseline questionnaire. Results. - Of the 5388 patients enrolled, 3953 (73%) completed at least one follow-up and 3183 (59%) completed two follow-up reports. Patients reported the following outcomes for attacks treated with the rizatriptan tablet and orally disintegrating tablet formulations, respectively, compared with their prior responses to oral usual care medications (P<.05 in all comparisons with baseline data): onset of pain relief within 30 minutes postdose: 18% and 23% versus 16%; no or mild headache 2 hours postdose: 66% and 67% versus 37%; largely symptom-free within 2 hours postdose: 52% and 54% versus 35%; return to usual activities within 2 hours postdose: 50% and 51% versus 31%; and very or somewhat satisfied with treatment: 72% and 74% versus 53%. Conclusions. - In this "real-world" setting involving a patient population selected by clinicians, rizatriptan appeared to offer better treatment outcomes than those from prior treatments with other oral migraine medications.

AB - Objective. - To evaluate the effectiveness of rizatriptan for acute migraine treatment and patient satisfaction with the drug in usual clinical practice settings. Background. - Although rizatriptan has been shown to effectively relieve migraine symptoms in clinical trials, we wished to assess its utility in typical patient care settings. Design. - Multicenter, open-label design involving the patients of practicing clinicians. Methods. - Adult migraineurs treated two migraine attacks with either rizatriptan 10-mg standard tablets or rizatriptan 10-mg orally disintegrating tablets in a crossover manner. Participants had not taken rizatriptan previously and chose which formulation to take first. Patients reported their treatment experiences via an interactive voice response system approximately 24 hours after treatment. Prior migraine treatment experiences were reported by patients on a baseline questionnaire completed at participating clinics. We used conditional logistic regression analysis adjusted for treatment sequences to test the statistical significance of comparisons with results recorded on the baseline questionnaire. Results. - Of the 5388 patients enrolled, 3953 (73%) completed at least one follow-up and 3183 (59%) completed two follow-up reports. Patients reported the following outcomes for attacks treated with the rizatriptan tablet and orally disintegrating tablet formulations, respectively, compared with their prior responses to oral usual care medications (P<.05 in all comparisons with baseline data): onset of pain relief within 30 minutes postdose: 18% and 23% versus 16%; no or mild headache 2 hours postdose: 66% and 67% versus 37%; largely symptom-free within 2 hours postdose: 52% and 54% versus 35%; return to usual activities within 2 hours postdose: 50% and 51% versus 31%; and very or somewhat satisfied with treatment: 72% and 74% versus 53%. Conclusions. - In this "real-world" setting involving a patient population selected by clinicians, rizatriptan appeared to offer better treatment outcomes than those from prior treatments with other oral migraine medications.

KW - Migraine

KW - Rizatriptan

KW - Treatment

KW - Usual clinic practice

UR - http://www.scopus.com/inward/record.url?scp=0037345850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037345850&partnerID=8YFLogxK

U2 - 10.1046/j.1526-4610.2003.03045.x

DO - 10.1046/j.1526-4610.2003.03045.x

M3 - Article

C2 - 12603640

AN - SCOPUS:0037345850

VL - 43

SP - 223

EP - 230

JO - Headache

JF - Headache

SN - 0017-8748

IS - 3

ER -